Form 4 for BNGO Bionano Genomics, Inc.
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-15 · accession 0001411690-25-000017 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-19 | 2025-02-15 | BNGO | Holmlin R. Erik | Pres, CEO, Dir | F - Tax | $5.73 | -51 | 1,981 | -3% | -$292.23 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-15 | F | D | 51 | $5.73 | 1,981 | D | — | — | (F1) The reporting person is reporting the withholding by the Issuer of an aggregate of 51 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. (F2) On January 24, 2025, the common stock of Bionano Genomics, Inc. split 1-for-60, resulting in the reporting person's ownership of 120,428 less shares of common stock (119,934 less shares held directly and 494 less shares held indirectly). (F3) Includes 2 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan on June 10, 2024 (As adjusted for the January 2025 Reverse Stock Split). |